Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates

Transfusion

Volumn 54, Issue 3, 2014, Pages 577-584

  Loh, Yen S ^a   Johnson, Lacey ^a   Kwok, Matthew ^a   Marks, Denese C ^a  

^a Research and Development   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE;

ARTICLE; CELL INTERACTION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; PATHOGEN REDUCTION SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPERNATANT; THROMBOCYTE;

BLOOD PLATELETS; BLOOD PRESERVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; P-SELECTIN; PLATELET TRANSFUSION;

EID: 84896057737     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12320     Document Type: Article

References (32)

1. Blajchman MA, Goldman M, Baeza F,. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004; 18: 11-24.
2. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-885.
3. Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, Matheson I, Murphy K, Preiksaitis J, Devine D,. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010; 50: 2592-2606.
4. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY,. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 (Suppl 2): 1S-29S.
5. Goodrich RP, Edrich RA, Li J, Seghatchian J,. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
6. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP,. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
7. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P,. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-285.
8. Janetzko K, Hinz K, Marschner S, Goodrich R, Kluter H,. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 2009; 97: 234-239.
9. Johnson L, Winter KM, Reid S, Hartkopf-Theis T, Marschner S, Goodrich RP, Marks DC,. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101: 208-214.
10. Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, Johansson PI,. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50: 2210-2219.
11. Picker SM, Steisel A, Gathof BS,. Evaluation of white blood cell- and platelet-derived cytokine accumulation in MIRASOL-PRT-treated platelets. Transfus Med Hemother 2009; 36: 114-120.
12. Li N,. Platelet-lymphocyte cross-talk. J Leukoc Biol 2008; 83: 1069-1078.
13. Koike J, Nagata K, Kudo S, Tsuji T, Irimura T,. Density-dependent induction of TNF-alpha release from human monocytes by immobilized P-selectin. FEBS Lett 2000; 477: 84-88.
14. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA,. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest 1995; 95: 2297-2303.
15. Cognasse F, Hamzeh-Cognasse H, Lafarge S, Acquart S, Chavarin P, Courbil R, Fabrigli P, Garraud O,. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro study. Transfusion 2009; 49: 91-98.
16. Gawaz M, Brand K, Dickfeld T, Pogatsa-Murray G, Page S, Bogner C, Koch W, Schomig A, Neumann F,. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75-85.
17. Zarbock A, Polanowska-Grabowska RK, Ley K,. Platelet-neutrophil- interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99-111.
18. Garcia BA, Smalley DM, Cho H, Shabanowitz J, Ley K, Hunt DF,. The platelet microparticle proteome. J Proteome Res 2005; 4: 1516-1521.
19. Ruebsaamen K, Liebisch G, Boettcher A, Schmitz G,. Lipidomic analysis of platelet senescence. Transfusion 2010; 50: 1665-1676.
20. Morrell CN,. Immunomodulatory mediators in platelet transfusion reactions. Hematology Am Soc Hematol Educ Program 2011; 2011: 470-474.
21. Caudrillier A, Looney MR,. Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury. Curr Pharm Des 2012; 18: 3260-3266.
22. Mine S, Fujisaki T, Suematsu M, Tanaka Y,. Activated platelets and endothelial cell interaction with neutrophils under flow conditions. Intern Med 2001; 40: 1085-1092.
23. Alexander C, Rietschel ET,. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001; 7: 167-2025.
24. Suzuki J, Hamada E, Shodai T, Kamoshida G, Kudo S, Itoh S, Koike J, Nagata K, Irimura T, Tsuji T,. Cytokine secretion from human monocytes potentiated by P-selectin-mediated cell adhesion. Int Arch Allergy Immunol 2013; 160: 152-160.
25. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA,. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-1534.
26. Blumberg N, Heal JM, Rowe JM,. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]. BMC Blood Disord 2004; 4: 6.
27. Kluter H, Bubel S, Kirchner H, Wilhelm D,. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999; 39: 1179-1184.
28. Vo TD, Cowles J, Heal JM, Blumberg N,. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus Med 2001; 11: 45-47.
29. Patterson BJ, Freedman J, Blanchette V, Sher G, Pinkerton P, Hannach B, Meharchand J, Lau W, Boyce N, Pinchefsky E, Tasev T, Pinchefsky J, Poon S, Shulman L, Mac KP, Thomas K, Blanchette N, Greenspan D, Panzarella T,. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med 2000; 10: 199-206.
30. Blumberg N, Heal JM, Liesveld JL, Phillips GL, Rowe JM,. Platelet transfusion and survival in adults with acute leukemia. Leukemia 2008; 22: 631-635.
31. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR,. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996; 93: 11877-11882.
32. Vetlesen A, Mirlashari MR, Akkök CA, Kelher MR, Khan SY, Silliman CC, Kjeldsen-Kragh J,. Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates. Transfusion 2013; 53: 147-155.